원료의약품 시장 규모, 점유율, 동향 분석 보고서 : 합성 유형별, 제조업체 유형별, 유형별, 용도별, 지역별, 부문 예측(2025-2030년)

Active Pharmaceutical Ingredients Market Growth & Trends:

The global active pharmaceutical ingredients market size is anticipated to reach USD 359.45 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 5.85% from 2025 to 2030. The market is driven by the growth of the biopharmaceutical sector, advancements in active pharmaceutical Ingredients (API) manufacturing, and an increase in the geriatric population.

The growth of the captive API segment is propelled by companies investing in solving challenges and developing new chemical ways for the production of APIs in-house. This aids in reducing costs and the risk of contamination. Artificial intelligence and protein synthesis are expected to facilitate faster development with greater control over the process.

The rising prevalence of chronic and lifestyle-based conditions, such as cardiovascular diseases, is accelerating the demand for API. For instance, as per U.S. Pharmacist in 2020, 47% of adults have at least one risk factor that supports cardiovascular disease development. Cardiovascular diseases are one of the global, critical public health burdens driving extensive R&D for APIs in the field.

The active pharmaceutical Ingredients market was positively influenced by the COVID-19 pandemic, as countries and significant players produce large quantities of components to meet the demand for the treatment of COVID-19. As a result of the outbreak, drug companies have changed the companies' strategies to focus on a larger patient population. To treat coronavirus, the U.S., for example, requested that HCQ be imported from India. The virus has also impacted Canada's medicine supply system, potentially causing complications for patients. The increasing importance of generics, rise in consumption of biopharmaceuticals, and expanding drug research and development activities for drug manufacturing are the primary drivers driving the growth of the market. However, the market's expansion is likely to be hampered by unfavorable drug price control regimes in several countries and high manufacturing costs.

Developing nations like India are receiving an increased preference in the market over dominant API market countries, like China, owing to geopolitical situations. Furthermore, India has quality raw materials and products, a large workforce, a vast distribution network, and government subsidies through the "Make in India" program.

To address unmet medical needs, companies are collaborating to develop novel treatments. This allows firms to use their resources to aid in the development of products and enhance the supply chain. In November 2021, Merck & Co Inc. announced that it has acquired Acceleron Pharma, this acquisition would help Merck & Co to expand their cardiovascular portfolio and pipeline.

Active Pharmaceutical Ingredients Market Report Highlights:

• Innovative APIs held the largest share of 62.0% in 2024, owing to increasing research and development activities for novel drug development and positive government initiatives
• Captive APIs segment held the largest market share of 51.03% in 2024
• The synthetic API segment dominated the market with the largest revenue share of 70.66% in 2024, owing to the higher availability of raw materials and easier protocols for the synthesis of these molecules
• North America accounted for the largest revenue share of 38.26% in 2024 and is expected to maintain its lead over the forecast period. This is attributed to the rising epidemiology of cancer, along with other lifestyle-induced diseases, thus encouraging the R&D activities, thereby boosting the market growth

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation
  • 1.1.1. Market Definitions
• 1.2. Objectives
  • 1.2.1. Objective - 1
  • 1.2.2. Objective - 2
  • 1.2.3. Objective - 3
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. List of Primary Sources

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Active Pharmaceutical Ingredients Market: Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers
  • 3.4.1. Increasing geriatric population
  • 3.4.2. Rising prevalence of target diseases such as hospital-acquired infections, genetic, cardiovascular, and neurological diseases
  • 3.4.3. Increasing preference for targeted therapy approach in cancer treatment
  • 3.4.4. Increasing preference for outsourcing APIs
• 3.5. Market Restraint Analysis
  • 3.5.1. High capital investments and production cost
  • 3.5.2. Stringent Safety and handling regulations regarding APIs
• 3.6. Business Environment Analysis
  • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
  • 3.6.2. Porter's Five Forces Analysis

Chapter 4. Active Pharmaceutical Ingredients Market: Type of Synthesis Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Active Pharmaceutical Ingredients Market: Type of Synthesis Movement Analysis
• 4.3. Active Pharmaceutical Ingredients Market by Type of Synthesis Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Biotic APIs
  • 4.5.1. Biotic APIs Market, 2018 - 2030 (USD Billion)
    • 4.5.1.1. Biotech APIs Market, By Type (Revenue, USD Billion, 2018 - 2030)
    • 4.5.1.2. Generic APIs
      • 4.5.1.2.1. Generic APIs Market, 2018 - 2030 (USD Billion)
    • 4.5.1.3. Innovative APIs
      • 4.5.1.3.1. Innovative APIs Market, 2018 - 2030 (USD Billion)
    • 4.5.1.4. Biotech APIs Market, By Product (Revenue, USD Billion, 2018 - 2030)
    • 4.5.1.5. Monoclonal Antibodies
      • 4.5.1.5.1. Monoclonal Antibodies Market, 2018 - 2030 (USD Billion)
    • 4.5.1.6. Hormones
      • 4.5.1.6.1. Hormones Market, 2018 - 2030 (USD Billion)
    • 4.5.1.7. Cytokines
      • 4.5.1.7.1. Cytokines Market, 2018 - 2030 (USD Billion)
    • 4.5.1.8. Recombinant Proteins
      • 4.5.1.8.1. Recombinant Proteins Market, 2018 - 2030 (USD Billion)
    • 4.5.1.9. Therapeutic Enzymes
      • 4.5.1.9.1. Therapeutic Enzymes Market, 2018 - 2030 (USD Billion)
    • 4.5.1.10. Vaccines
      • 4.5.1.10.1. Vaccines Market, 2018 - 2030 (USD Billion)
    • 4.5.1.11. Blood Factors
      • 4.5.1.11.1. Blood Factors Market, 2018 - 2030 (USD Billion)
• 4.6. Synthetic APIs
  • 4.6.1. Synthetic APIs Market, 2018 - 2030 (USD Billion)
    • 4.6.1.1. Synthetic APIs Market, By Type (Revenue, USD Billion, 2018 - 2030)
    • 4.6.1.2. Generic APIs
      • 4.6.1.2.1. Generic APIs Market, 2018 - 2030 (USD Billion)
    • 4.6.1.3. Innovative APIs
      • 4.6.1.3.1. Innovative APIs Market, 2018 - 2030 (USD Billion)

Chapter 5. Active Pharmaceutical Ingredients Market: Type of Manufacturer Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Active Pharmaceutical Ingredients Market: Type Movement Analysis
• 5.3. Active Pharmaceutical Ingredients Market by Type Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Captive APIs
  • 5.5.1. Captive APIs Market, 2018 - 2030 (USD Billion)
• 5.6. Merchant APIs
  • 5.6.1. Merchant APIs Market, 2018 - 2030 (USD Billion)

Chapter 6. Active Pharmaceutical Ingredients Market: Type Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Active Pharmaceutical Ingredients Market: Type Movement Analysis
• 6.3. Active Pharmaceutical Ingredients Market by Type Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. Generic APIs
  • 6.5.1. Generic APIs Market, 2018 - 2030 (USD Billion)
• 6.6. Innovative APIs
  • 6.6.1. Innovative APIs Market, 2018 - 2030 (USD Billion)

Chapter 7. Active Pharmaceutical Ingredients Market: Application Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Active Pharmaceutical Ingredients Market: Application Movement Analysis
• 7.3. Active Pharmaceutical Ingredients Market by Application Outlook (USD Million)
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 7.5. Cardiovascular Diseases
  • 7.5.1. Cardiovascular Diseases Market, 2018 - 2030 (USD Billion)
• 7.6. Oncology
  • 7.6.1. Innovative APIs Oncology Market, 2018 - 2030 (USD Billion)
• 7.7. CNS and Neurology
  • 7.7.1. CNS and Neurology Market, 2018 - 2030 (USD Billion)
• 7.8. Orthopedic
  • 7.8.1. Orthopedic Market, 2018 - 2030 (USD Billion)
• 7.9. Endocrinology
  • 7.9.1. Endocrinology Market, 2018 - 2030 (USD Billion)
• 7.10. Pulmonology
  • 7.10.1. Pulmonology Market, 2018 - 2030 (USD Billion)
• 7.11. Gastroenterology
  • 7.11.1. Gastroenterology Market, 2018 - 2030 (USD Billion)
• 7.12. Nephrology
  • 7.12.1. Nephrology Market, 2018 - 2030 (USD Billion)
• 7.13. Ophthalmology
  • 7.13.1. Ophthalmology Market, 2018 - 2030 (USD Billion)
• 7.14. Others
  • 7.14.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 8. Active Pharmaceutical Ingredients Market: Type of Drug Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Active Pharmaceutical Ingredients Market: Type of Drug Movement Analysis
• 8.3. Active Pharmaceutical Ingredients Market by Type of Drug Outlook (USD Million)
• 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 8.5. Prescription
  • 8.5.1. Prescription Market, 2018 - 2030 (USD Billion)
• 8.6. OTC
  • 8.6.1. OTC Market, 2018 - 2030 (USD Billion)

Chapter 9. Active Pharmaceutical Ingredients Market: Regional Estimates & Trend Analysis

• 9.1. Regional Dashboard
• 9.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 9.3. North America
  • 9.3.1. North America Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • 9.3.2. U.S.
    • 9.3.2.1. Key Country Dynamics
    • 9.3.2.2. Target Disease Prevalence
    • 9.3.2.3. Competitive Scenario
    • 9.3.2.4. Regulatory Framework
    • 9.3.2.5. Reimbursement Scenario
    • 9.3.2.6. U.S. Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • 9.3.3. Canada
    • 9.3.3.1. Key Country Dynamics
    • 9.3.3.2. Target Disease Prevalence
    • 9.3.3.3. Competitive Scenario
    • 9.3.3.4. Regulatory Framework
    • 9.3.3.5. Reimbursement Scenario
    • 9.3.3.6. Canada Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • 9.3.4. Mexico
    • 9.3.4.1. Key Country Dynamics
    • 9.3.4.2. Target Disease Prevalence
    • 9.3.4.3. Competitive Scenario
    • 9.3.4.4. Regulatory Framework
    • 9.3.4.5. Reimbursement Scenario
    • 9.3.4.6. Mexico Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
• 9.4. Europe
  • 9.4.1. Europe Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • 9.4.2. Germany
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Target Disease Prevalence
    • 9.4.2.3. Competitive Scenario
    • 9.4.2.4. Regulatory Framework
    • 9.4.2.5. Reimbursement Scenario
    • 9.4.2.6. Germany Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • 9.4.3. UK
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Target Disease Prevalence
    • 9.4.3.3. Competitive Scenario
    • 9.4.3.4. Regulatory Framework
    • 9.4.3.5. Reimbursement Scenario
    • 9.4.3.6. UK Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • 9.4.4. France
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Target Disease Prevalence
    • 9.4.4.3. Competitive Scenario
    • 9.4.4.4. Regulatory Framework
    • 9.4.4.5. Reimbursement Scenario
    • 9.4.4.6. France Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • 9.4.5. Italy
    • 9.4.5.1. Key Country Dynamics
    • 9.4.5.2. Target Disease Prevalence
    • 9.4.5.3. Competitive Scenario
    • 9.4.5.4. Regulatory Framework
    • 9.4.5.5. Reimbursement Scenario
    • 9.4.5.6. Italy Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • 9.4.6. Spain
    • 9.4.6.1. Key Country Dynamics
    • 9.4.6.2. Target Disease Prevalence
    • 9.4.6.3. Competitive Scenario
    • 9.4.6.4. Regulatory Framework
    • 9.4.6.5. Reimbursement Scenario
    • 9.4.6.6. Spain Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • 9.4.7. Denmark
    • 9.4.7.1. Key Country Dynamics
    • 9.4.7.2. Target Disease Prevalence
    • 9.4.7.3. Competitive Scenario
    • 9.4.7.4. Regulatory Framework
    • 9.4.7.5. Reimbursement Scenario
    • 9.4.7.6. Denmark Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • 9.4.8. Sweden
    • 9.4.8.1. Key Country Dynamics
    • 9.4.8.2. Target Disease Prevalence
    • 9.4.8.3. Competitive Scenario
    • 9.4.8.4. Regulatory Framework
    • 9.4.8.5. Reimbursement Scenario
    • 9.4.8.6. Sweden Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • 9.4.9. Norway
    • 9.4.9.1. Key Country Dynamics
    • 9.4.9.2. Target Disease Prevalence
    • 9.4.9.3. Competitive Scenario
    • 9.4.9.4. Regulatory Framework
    • 9.4.9.5. Reimbursement Scenario
    • 9.4.9.6. Norway Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
• 9.5. Asia Pacific
  • 9.5.1. Asia Pacific Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • 9.5.2. Japan
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Target Disease Prevalence
    • 9.5.2.3. Competitive Scenario
    • 9.5.2.4. Regulatory Framework
    • 9.5.2.5. Reimbursement Scenario
    • 9.5.2.6. Japan Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • 9.5.3. China
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Target Disease Prevalence
    • 9.5.3.3. Competitive Scenario
    • 9.5.3.4. Regulatory Framework
    • 9.5.3.5. Reimbursement Scenario
    • 9.5.3.6. China Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • 9.5.4. India
    • 9.5.4.1. Key Country Dynamics
    • 9.5.4.2. Target Disease Prevalence
    • 9.5.4.3. Competitive Scenario
    • 9.5.4.4. Regulatory Framework
    • 9.5.4.5. Reimbursement Scenario
    • 9.5.4.6. India Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • 9.5.5. South Korea
    • 9.5.5.1. Key Country Dynamics
    • 9.5.5.2. Target Disease Prevalence
    • 9.5.5.3. Competitive Scenario
    • 9.5.5.4. Regulatory Framework
    • 9.5.5.5. Reimbursement Scenario
    • 9.5.5.6. South Korea Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • 9.5.6. Australia
    • 9.5.6.1. Key Country Dynamics
    • 9.5.6.2. Target Disease Prevalence
    • 9.5.6.3. Competitive Scenario
    • 9.5.6.4. Regulatory Framework
    • 9.5.6.5. Reimbursement Scenario
    • 9.5.6.6. Australia Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • 9.5.7. Thailand
    • 9.5.7.1. Key Country Dynamics
    • 9.5.7.2. Target Disease Prevalence
    • 9.5.7.3. Competitive Scenario
    • 9.5.7.4. Regulatory Framework
    • 9.5.7.5. Reimbursement Scenario
    • 9.5.7.6. Thailand Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
• 9.6. Latin America
  • 9.6.1. Latin America Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • 9.6.2. Brazil
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Target Disease Prevalence
    • 9.6.2.3. Competitive Scenario
    • 9.6.2.4. Regulatory Framework
    • 9.6.2.5. Reimbursement Scenario
    • 9.6.2.6. Brazil Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • 9.6.3. Argentina
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Target Disease Prevalence
    • 9.6.3.3. Competitive Scenario
    • 9.6.3.4. Regulatory Framework
    • 9.6.3.5. Reimbursement Scenario
    • 9.6.3.6. Argentina Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
• 9.7. MEA
  • 9.7.1. MEA Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • 9.7.2. South Africa
    • 9.7.2.1. Key Country Dynamics
    • 9.7.2.2. Target Disease Prevalence
    • 9.7.2.3. Competitive Scenario
    • 9.7.2.4. Regulatory Framework
    • 9.7.2.5. Reimbursement Scenario
    • 9.7.2.6. South Africa Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • 9.7.3. Saudi Arabia
    • 9.7.3.1. Key Country Dynamics
    • 9.7.3.2. Target Disease Prevalence
    • 9.7.3.3. Competitive Scenario
    • 9.7.3.4. Regulatory Framework
    • 9.7.3.5. Reimbursement Scenario
    • 9.7.3.6. Saudi Arabia Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • 9.7.4. UAE
    • 9.7.4.1. Key Country Dynamics
    • 9.7.4.2. Target Disease Prevalence
    • 9.7.4.3. Competitive Scenario
    • 9.7.4.4. Regulatory Framework
    • 9.7.4.5. Reimbursement Scenario
    • 9.7.4.6. UAE Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)
  • 9.7.5. Kuwait
    • 9.7.5.1. Key Country Dynamics
    • 9.7.5.2. Target Disease Prevalence
    • 9.7.5.3. Competitive Scenario
    • 9.7.5.4. Regulatory Framework
    • 9.7.5.5. Reimbursement Scenario
    • 9.7.5.6. Kuwait Active pharmaceutical ingredients market, 2018 - 2030 (USD Billion)

Chapter 10. Competitive Landscape

• 10.1. Participant's overview
• 10.2. Financial performance
• 10.3. Participant categorization
  • 10.3.1. Market Leaders
  • 10.3.2. Active Pharmaceutical Ingredients Market Share Analysis, 2024
  • 10.3.3. Company Profiles
    • 10.3.3.1. Dr. Reddy's Laboratories Ltd.
      • 10.3.3.1.1. Company Overview
      • 10.3.3.1.2. Financial Performance
      • 10.3.3.1.3. Product Benchmarking
      • 10.3.3.1.4. Strategic Initiatives
    • 10.3.3.2. Sun Pharmaceutical Industries Ltd.
      • 10.3.3.2.1. Company Overview
      • 10.3.3.2.2. Financial Performance
      • 10.3.3.2.3. Product Benchmarking
      • 10.3.3.2.4. Strategic Initiatives
    • 10.3.3.3. Teva Pharmaceutical Industries Ltd.
      • 10.3.3.3.1. Company Overview
      • 10.3.3.3.2. Financial Performance
      • 10.3.3.3.3. Product Benchmarking
      • 10.3.3.3.4. Strategic Initiatives
    • 10.3.3.4. Cipla Inc.
      • 10.3.3.4.1. Company Overview
      • 10.3.3.4.2. Financial Performance
      • 10.3.3.4.3. Product Benchmarking
      • 10.3.3.4.4. Strategic Initiatives
    • 10.3.3.5. AbbVie Inc.
      • 10.3.3.5.1. Company Overview
      • 10.3.3.5.2. Financial Performance
      • 10.3.3.5.3. Product Benchmarking
      • 10.3.3.5.4. Strategic Initiatives
    • 10.3.3.6. Aurobindo Pharma
      • 10.3.3.6.1. Company Overview
      • 10.3.3.6.2. Financial Performance
      • 10.3.3.6.3. Product Benchmarking
      • 10.3.3.6.4. Strategic Initiatives
    • 10.3.3.7. Sandoz International GmbH (Novartis AG)
      • 10.3.3.7.1. Company Overview
      • 10.3.3.7.2. Financial Performance
      • 10.3.3.7.3. Product Benchmarking
      • 10.3.3.7.4. Strategic Initiatives
    • 10.3.3.8. Viatris Inc.
      • 10.3.3.8.1. Company Overview
      • 10.3.3.8.2. Financial Performance
      • 10.3.3.8.3. Product Benchmarking
      • 10.3.3.8.4. Strategic Initiatives
    • 10.3.3.9. Fresenius Kabi AG
      • 10.3.3.9.1. Company Overview
      • 10.3.3.9.2. Financial Performance
      • 10.3.3.9.3. Product Benchmarking
      • 10.3.3.9.4. Strategic Initiatives
    • 10.3.3.10. STADA Arzneimittel AG
      • 10.3.3.10.1. Company Overview
      • 10.3.3.10.2. Financial Performance
      • 10.3.3.10.3. Product Benchmarking
      • 10.3.3.10.4. Strategic Initiatives